Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Brown, Jennifer R. [1 ]
Eichhorst, Barbara [2 ]
Ghia, Paolo [3 ,4 ]
Kater, A. P. [5 ]
Li, Jianyong [6 ]
Khurana, Sudha [7 ]
Elhamy, Mostafa [7 ]
Wang, Min Hui [7 ]
Seymour, John F. [8 ,9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Hosp Cologne, Cologne, Germany
[3] Univ Vita Salute Raffaele, Milan, Italy
[4] IRCCS Osped San Raffaele, Milan, Italy
[5] Amsterdam UMC, Amsterdam, Netherlands
[6] Nanjing Med Univ, Affiliated Hosp 1, Jiansu Sheng, Peoples R China
[7] Acerta Pharma, San Francisco, CA USA
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
CLL; chronic lymphocytic leukemia; acalabrutinib; Bruton tyrosine kinase inhibitor; combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-092
引用
收藏
页码：S221 / S222
页数：2
相关论文
共 50 条
  • [41] Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
    Danilov, Alexey V.
    Herbaux, Charles
    Walter, Harriet S.
    Hillmen, Peter
    Rule, Simon A.
    Kio, Ebenezer A.
    Karlin, Lionel
    Dyer, Martin J. S.
    Mitra, Siddhartha S.
    Yi, Ping Cheng
    Humeniuk, Rita
    Huang, Xi
    Zhou, Ziqian
    Bhargava, Pankaj
    Jurgensmeier, Juliane M.
    Fegan, Christopher D.
    CLINICAL CANCER RESEARCH, 2020, 26 (12) : 2810 - 2818
  • [42] Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine
    Danilov, Alexey, V
    Yimer, Habte A.
    Boxer, Michael A.
    Burke, John M.
    Babu, Sunil
    Li, Jia
    Mun, Yong
    Trask, Peter C.
    Masaquel, Anthony S.
    Sharman, Jeff P.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (02) : 121 - 128
  • [43] Changes in Proteome of CLL (Chronic Lymphocytic Leukemia) Lymphocytes During Investigator-Initiated Trial of Ibrutinib Alone and in Combination With Venetoclax in Treatment-Naive Patients With CLL
    Timofeeva, Natalia
    Jain, Nitin
    Irajizad, Ehsan
    Aslan, Burcu
    Katayama, Hiroyuki
    Cai, Yining
    Ayres, Mary
    Iles, Lakesla
    Vykoukal, Jody
    Dennison, Jennifer
    Hanash, Samir
    Wierda, William
    Gandhi, Varsha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S283 - S283
  • [44] Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia
    Opat, Stephen
    Awan, Farrukh T.
    Fogliatto, Laura
    Nikitin, Eugene
    Czerwinski, Joanna
    Alves da Silva, Rodrigo Santucci
    Jujjavarapu, Srinivas
    Samoilova, Olga
    Dartigeas, Caroline
    Tran, Hoa
    de la Serna, Javier
    Banerji, Versha
    Magnano Mayer, Laura
    Hart, Jason
    von Tresckow, Julia
    Poulsen, Christian B.
    Eom, Ki Seong
    Merli, Michele
    John, Ellie
    Munley, Jiefen
    Hakre, Shweta
    Hermann, Richard
    Niemann, Carsten U.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S347 - S347
  • [45] Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View
    Do, Ngoc
    Thielen, Frederick W.
    VALUE IN HEALTH, 2023, 26 (04) : 477 - 486
  • [46] Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia
    Soumerai, Jacob D.
    Davids, Matthew S.
    Werner, Lillian
    Fisher, David C.
    Armand, Philippe
    Amrein, Philip C.
    Neuberg, Donna
    Hochberg, Ephraim P.
    Brown, Jennifer R.
    Abramson, Jeremy S.
    LEUKEMIA & LYMPHOMA, 2019, 60 (12) : 2931 - 2938
  • [47] Chemoimmunotherapy with modified dosing of fludarabine, cyclophosphamide, and rituximab shows significant clinical activity in patients with previously untreated chronic lymphocytic leukemia
    Nicole Lamanna
    Mark A. Weiss
    Current Hematologic Malignancy Reports, 2009, 4 (4) : 185 - 186
  • [48] Chemoimmunotherapy May Overcome the Adverse Prognostic Significance of 11q Deletion in Previously Untreated Patients With Chronic Lymphocytic Leukemia
    Tsimberidou, Apostolia-Maria
    Tam, Constantine
    Abruzzo, Lynne V.
    O'Brien, Susan
    Wierda, William G.
    Lerner, Susan
    Kantarjian, Hagop M.
    Keating, Michael J.
    CANCER, 2009, 115 (02) : 373 - 380
  • [49] Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia
    Feugier, Pierre
    Aurran, Therese
    Mahe, Beatrice
    Letestu, Remi
    Nguyen-Khac, Florence
    Cazin, Bruno
    Tournilhac, Olivier
    Maisonneuve, Herve
    Casasnovas, Olivier
    Delmer, Alain
    Leblond, Veronique
    Royer, Bruno
    Corront, Bernadette
    Chevret, Sylvie
    Delepine, Roselyne
    Vaudaux, Sandrine
    Van den Neste, Eric
    Bene, Marie-Christine
    Cymbalista, Florence
    Ross-Weil, Damien
    Lepretre, Stephane
    HAEMATOLOGICA, 2018, 103 (07) : E304 - E306
  • [50] Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study
    Byrd, John C.
    Woyach, Jennifer A.
    Furman, Richard R.
    Martin, Peter
    O'Brien, Susan
    Brown, Jennifer R.
    Stephens, Deborah M.
    Barrientos, Jacqueline C.
    Devereux, Stephen
    Hillmen, Peter
    Pagel, John M.
    Chen, Dih-Yih
    Hamdy, Ahmed
    Izumi, Raquel
    Patel, Priti
    Wang, Min Hui
    Jain, Nitin
    Wierda, William G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S283 - S283
12345